GARDP announces ‘5 BY 25’ goal in response to the growing burden of antibiotic resistant infections

  29 June 2019

Today GARDP announces its ‘5 BY 25’ goal to deliver five new treatments in response to the growing global threat of antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally per year.1 GARDP’s five treatments will focus on the priority bacterial pathogens identified by the World Health Organization (WHO).

GARDP’s Chair of the Board, Professor Ramanan Laxminarayan said, “We are in a race against time to develop new antibiotics and make them accessible to the millions of people who need them. GARDP’s remarkable progress over the last three years in building strong partnerships and a talented team positions it well to meet this ambitious new goal. We need to work together with all stakeholders, including governments, academia and civil society, philanthropic organizations and the private sector, to make this goal a reality.

Further reading: GARDP
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!